Palatin Launches reconnectstudy.com in Support of Bremelanotide Phase 3 Program for Female Sexual Dysfunction
CRANBURY, N.J., Feb. 20, 2015 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced that it has launched a clinical trial website (https://www.reconnectstudy.com) in support of its phase 3 reconnect study with bremelanotide for …